Physician profile
Ajith Karayil
NPI 1104011618
$15,736.71
in general payments reported to CMS, 2019-2025
35 companies · $1,664 in 2025
The $1,664 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,185 · 2020: $2,387 · 2021: $3,630 · 2022: $2,413 · 2023: $1,599 · 2024: $1,860 · 2025: $1,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,123.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,376.83 | 2019-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $2,975.76 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,693.97 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,553.99 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $1,150.41 | 2019-2025 | Verquvo, Steglatro |
| Lilly USA, LLC | $689.42 | 2019-2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $492.36 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $416.55 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $415.44 | 2020-2025 | Xifaxan |
| Amarin Pharma, INC. | $290.38 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $266.21 | 2024-2025 | Rexulti |
| Abbott Laboratories | $243.00 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $235.37 | 2021-2025 | |
| Corcept Therapeutics | $229.17 | 2023-2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $204.34 | 2019-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $180.87 | 2022-2024 | Yupelri |
| Abbvie INC. | $162.47 | 2021-2025 | |
| Exact Sciences Corporation | $147.95 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $138.97 | 2020-2024 | |
| Teva Pharmaceuticals USA, INC. | $137.62 | 2020 | |
| Avanir Pharmaceuticals, INC. | $125.98 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $125.00 | 2025 | Fanapt |
| Amgen INC. | $104.89 | 2020-2024 | Repatha, Otezla |
| Allergan, INC. | $87.61 | 2019-2020 | |
| Vifor Pharma, INC. | $68.02 | 2021-2022 | |
| Melinta Therapeutics, LLC | $34.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.32 | 2019 | |
| Gilead Sciences, INC. | $30.22 | 2022 | |
| Scpharmaceuticals INC. | $21.44 | 2025 | |
| Mannkind Corporation | $19.77 | 2019 | |
| Radius Health, INC. | $19.03 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.85 | 2021 | |
| Astellas Pharma US INC | $16.60 | 2019 | |
| Horizon Therapeutics Plc | $15.12 | 2022 | |
| Esperion Therapeutics, INC. | $14.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajith Karayil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.